NEW YORK (GenomeWeb News) – Exact Sciences today priced its public offering of 5.5 million shares of its common stock at $12.35 per share with anticipated net proceeds of about $63.7 million.

The company announced the offering after the close of the market on Monday and has filed a shelf registration with the US Securities and Exchange Commission. Jefferies and R.W. Baird are joint book-running managers for the proposed offering. William Blair, Canaccord Genuity, and Mizuho Securities are co-managers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.